James Wert
Medical Oncology · Hudson, FLNPI 1215497334
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 10.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,670, more than ten times the $26 reported in 2022. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 139 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$294
- Incyte Corporation$287
- Merck$267
- AstraZeneca$263
- AVEO Pharmaceuticals, Inc.$171
- Sanofi$139
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,74897%
- Education$903%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $294 |
| Incyte Corporation | 21 | $287 |
| Merck | 13 | $267 |
| AstraZeneca(2 entities) | 11 | $263 |
| AVEO Pharmaceuticals, Inc. | 5 | $171 |
| Sanofi | 7 | $139 |
| Bristol Myers Squibb | 5 | $111 |
| Johnson & Johnson | 5 | $101 |
| Gilead(2 entities) | 3 | $85 |
| Bayer | 4 | $85 |
| Pfizer | 4 | $80 |
| Novartis | 4 | $78 |
| AbbVie | 3 | $69 |
| GSK | 3 | $56 |
| Puma Biotechnology, Inc. | 3 | $53 |
| Boehringer Ingelheim | 3 | $52 |
| Rigel Pharmaceuticals, Inc. | 2 | $49 |
| Novo Nordisk | 2 | $43 |
| Pharmaessentia USA Corporation | 2 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Karyopharm Therapeutics Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $37 |
| Exelixis Inc. | 2 | $36 |
| Array Biopharma Inc | 2 | $33 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Tersera Therapeutics LLC | 1 | $32 |
| Sobi, Inc | 1 | $30 |
| Adaptive Biotechnologies Corporation | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Stemline Therapeutics Inc. | 1 | $24 |
| ADC Therapeutics America, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| EMD Serono, Inc. | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
How this compares
$2,838 in reported general payments places this provider in the 25th percentile of 507 medical oncology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 12 | $404 |
| Oxycodone Hcl | 11 | $141 |
| Letrozole | 12 | $118 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Hudson
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.